Benchmarking Dendritic Cells Against Other Vaccine Platforms to Reveal Advantages & Overcoming Challenges, Helping Advance Effective Cancer Vaccines

• Evaluating dendritic cell vaccine platforms against RNA, peptide and viral vector based approaches to select the most clinically relevant approach
• Highlighting molecular and cellular features of effective dendritic cell vaccines, including overcoming challenges with abnormal differentiation
• Uncovering strategies for preventing cancer recurrence and improving treatments for the patients in need

Speakers:

Keith Knutson

Professor, Immunology

Mayo Clinic